Biopharma Funding Levels Reach ‘New Normal’ Until Federal Interest Rates Change: PitchBook
1. Biopharma Funding Levels Stabilize: Biopharma funding levels have reached a "new normal" and are expected to remain stable until federal interest rates change, according to PitchBook.
2. Federal Interest Rates Impact: The current interest rate environment has led to a shift in biopharma investment trends, with funding levels staying relatively stable quarter-over-quarter.
3. Venture Capital Exit Multiples: Venture capital exit multiples are influenced by industry, company stage, quality, market conditions, and exit type, and are a key metric for measuring portfolio company performance and investor returns.
4. Global Venture Capital Fundraising: Global venture capital fundraising has slowed down, with $30.4 billion raised in Q1 2024, indicating a challenging fundraising environment for VCs.